



## RepSox

Catalog No: tcsc1321

Available Sizes		
Size: 5mg		
Size: 10mg		
Size: 50mg		
Specifications		
<b>CAS No:</b> 446859-33-2		
Formula: C <sub>17</sub> H <sub>13</sub> N <sub>5</sub>		
<b>Pathway:</b> TGF-beta/Smad		
<b>Target:</b> TGF-β Receptor		
Purity / Grade: >98%		
<b>Solubility:</b> DMSO : ≥ 52 mg/mL (180.98 mM)		
<b>Alternative Names:</b> E-616452;SJN 2511		
Observed Molecular Weight:		

## **Product Description**

287.32





RepSox is a potent and selective of the  $TGF\beta R-1/ALK5$  inhibitor, inhibits ALK5 autophosphorylation with  $IC_{50}$  of 4 nM.

IC50 & Target: IC50: 4 nM (ALK5 autophosphorylation)<sup>[1]</sup>

In Vitro: RepSox also inhibits ATP binding to ALK5 with IC $_{50}$  of 23 nM. RepSox shows potent activity in both binding and cellular assays and exhibits selectivity over p38 mitogen-activated protein kinase. with IC $_{50}$  of >16  $\mu$ M $^{[1]}$ . RepSox act s as an inhibitor of the Tgf $\beta$ 1 kinase. Treatment with 25  $\mu$ M RepSox almost completely eliminates Smad3 phosphorylation, indicating that RepSox strongly inhibits Tgf $\beta$  signaling in somatic cells. RepSox is most effective at replacing Sox2 during days 10-11 after transduction and that therefore cultures of Oct4, Klf4, and cMyc-transduced MEFs give rise to intermediates capable of responding to RepSox treatment. These intermediates appear at day 4 post-transduction and peak at days 10-11. Treatment with RepSox decreased the proportion of cells in  $G_2$ /M phase of the cell cycle, indicating it does not increase the proliferation rate of these partially reprogrammed cells $^{[2]}$ .

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!